MEMPHIS, TN - May 18, 2009 - ACORN CRO, an oncology -focused CRO, has developed proprietary technology known as STAR (Site Tracking And Recruitment). The introduction of this dedicated technology tool will speed the site selection process as it automates the study feasibility process. "STAR was developed under the guidance of ACORN CRO's experienced project managers who sought to save valuable time during the study start-up phase. The resulting system delivers solutions that provide meaningful cost benefits to both sponsors and participating sites," remarked Edward J. Stepanski, PhD, COO.
STAR increases transparency and efficiency in the study feasibility/site selection process. The Site Repository contains all known information about each oncology research site, and enables rapid selection of potential study sites based upon sponsor/study requirements. It also reduces the need for sites to complete repetitive tasks and is estimated to save approximately 75% of the time sites traditionally spend on com pleting study feasibility forms. Through STAR, sponsors are able to v iew a report summarizing site identification metrics in real time. Sponsors will appreciate that STAR automatically sends reminder notifications throughout the process, allows complete tracking of the status of each site contacted, and reduces the time needed to definitively identify study sites.
"STAR is yet another way in which ACORN CRO leverages technology to provide added value and efficiency for its customers. STAR substantially speeds up the study start-up process which results in impressive economies of scale," added Kristie Lively, Vice President.
ACORN CRO will showcase STAR at the annual DIA meeting in San Diego, June 22-24, 2009 in booth #2039.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.